From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis

Surgical Oncology

Volumn 25, Issue 3, 2016, Pages 332-338

  Andreatos, Nikolaos ^a   Ronnekleiv Kelly, Sean ^a   Margonis, Georgios A ^a   Sasaki, Kazunari ^a   Gani, Faiz ^a   Amini, Neda ^a   Wilson, Ana ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Colorectal liver metastasis; KRAS

Indexed keywords

K RAS PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

CANCER RECURRENCE; CODON; COLORECTAL LIVER METASTASIS; GENETIC ASSOCIATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); CANCER STAGING; COLORECTAL NEOPLASMS; GENETICS; LIVER NEOPLASMS; LIVER RESECTION; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84978758602     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2016.07.002     Document Type: Review

References (41)

1. [1] Nathan, H., de Jong, M.C., Pulitano, C., Ribero, D., Strub, J., Mentha, G., Gigot, J.F., Schulick, R.D., Choti, M.A., Aldrighetti, L., Capussotti, L., Pawlik, T.M., Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J. Am. Coll. Surg., 210(5), 2010 755–64, 764–6.
2. [2] Brudvik, K.W., Kopetz, S.E., Li, L., Conrad, C., Aloia, T.A., Vauthey, J.N., Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br. J. Surg. 102:10 (2015), 1175–1183.
3. [3] Yordy, J.S., Muise-Helmericks, R.C., Signal transduction and the Ets family of transcription factors. Oncogene 19:55 (2000), 6503–6513.
4. [4] Chang, E.H., Gonda, M.A., Ellis, R.W., Scolnick, E.M., Lowy, D.R., Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc. Natl. Acad. Sci. U. S. A. 79:16 (1982), 4848–4852.
5. [5] Cejas, P., Lopez-Gomez, M., Aguayo, C., Madero, R., de Castro Carpeno, J., Belda-Iniesta, C., Barriuso, J., Moreno Garcia, V., Larrauri, J., Lopez, R., Casado, E., Gonzalez-Baron, M., Feliu, J., KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PloS One, 4(12), 2009, e8199.
6. [6] Samatar, A.A., Poulikakos, P.I., Targeting RAS-ERK signalling in cancer: promises and challenges, Nature reviews. Drug Discov. 13:12 (2014), 928–942.
7. [7] Feinberg, A.P., Vogelstein, B., Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111:1 (1983), 47–54.
8. [8] Bos, J.L., Fearon, E.R., Hamilton, S.R., Verlaan-de Vries, M., van Boom, J.H., van der Eb, A.J., Vogelstein, B., Prevalence of ras gene mutations in human colorectal cancers. Nature 327:6120 (1987), 293–297.
9. [9] Suchy, B., Zietz, C., Rabes, H.M., K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int. J. Cancer 52:1 (1992), 30–33.
10. [10] Kern, S.E., Fearon, E.R., Tersmette, K.W., Enterline, J.P., Leppert, M., Nakamura, Y., White, R., Vogelstein, B., Hamilton, S.R., Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. Jama 261:21 (1989), 3099–3103.
11. [11] Yaeger, R., Cowell, E., Chou, J.F., Gewirtz, A.N., Borsu, L., Vakiani, E., Solit, D.B., Rosen, N., Capanu, M., Ladanyi, M., Kemeny, N., RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121:8 (2015), 1195–1203.
12. [12] Vauthey, J.N., Zimmitti, G., Kopetz, S.E., Shindoh, J., Chen, S.S., Andreou, A., Curley, S.A., Aloia, T.A., Maru, D.M., RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann. Surg. 258:4 (2013), 619–626 discussion 626–7.
13. [13] Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61:5 (1990), 759–767.
14. [14] Tanaka, M., Omura, K., Watanabe, Y., Oda, Y., Nakanishi, I., Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J. Surg. Oncol. 57:1 (1994), 57–64.
15. [15] Tan, C., Du, X., KRAS mutation testing in metastatic colorectal cancer. World J. Gastroenterol 18:37 (2012), 5171–5180.
16. [16] Lipsyc, M., Yaeger, R., Impact of somatic mutations on patterns of metastasis in colorectal cancer. J. Gastrointest. Oncol. 6:6 (2015), 645–649.
17. [17] Lahti, S.J., Xing, M., Zhang, D., Lee, J.J., Magnetta, M.J., Kim, H.S., KRAS status as an independent prognostic factor for survival after Yttrium-90 radioembolization therapy for unresectable colorectal Cancer liver metastases. J. Vasc. Interven. Radiol. JVIR 26:8 (2015), 1102–1111.
18. [18] Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J., Dix, B.R., Iacopetta, B.J., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranek, M., Jandik, P., Benamouzig, R., Jullian, E., Laurent-Puig, P., Olschwang, S., Muller, O., Hoffmann, I., Rabes, H.M., Zietz, C., Troungos, C., Valavanis, C., Yuen, S.T., Ho, J.W., Croke, C.T., O'Donoghue, D.P., Giaretti, W., Rapallo, A., Russo, A., Bazan, V., Tanaka, M., Omura, K., Azuma, T., Ohkusa, T., Fujimori, T., Ono, Y., Pauly, M., Faber, C., Glaesener, R., de Goeij, A.F., Arends, J.W., Andersen, S.N., Lovig, T., Breivik, J., Gaudernack, G., Clausen, O.P., De Angelis, P.D., Meling, G.I., Rognum, T.O., Smith, R., Goh, H.S., Font, A., Rosell, R., Sun, X.F., Zhang, H., Benhattar, J., Losi, L., Lee, J.Q., Wang, S.T., Clarke, P.A., Bell, S., Quirke, P., Bubb, V.J., Piris, J., Cruickshank, N.R., Morton, D., Fox, J.C., Al-Mulla, F., Lees, N., Hall, C.N., Snary, D., Wilkinson, K., Dillon, D., Costa, J., Pricolo, V.E., Finkelstein, S.D., Thebo, J.S., Senagore, A.J., Halter, S.A., Wadler, S., Malik, S., Krtolica, K., Urosevic, N., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85:5 (2001), 692–696.
19. [19] Richman, S.D., Seymour, M.T., Chambers, P., Elliott, F., Daly, C.L., Meade, A.M., Taylor, G., Barrett, J.H., Quirke, P., KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27:35 (2009), 5931–5937.
20. [20] Nash, G.M., Gimbel, M., Shia, J., Nathanson, D.R., Ndubuisi, M.I., Zeng, Z.S., Kemeny, N., Paty, P.B., KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann. Surg. Oncol. 17:2 (2010), 572–578.
21. [21] Shoji, H., Yamada, Y., Taniguchi, H., Nagashima, K., Okita, N., Takashima, A., Honma, Y., Iwasa, S., Kato, K., Hamaguchi, T., Shimada, Y., Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 105:8 (2014), 1002–1007.
22. [22] Karagkounis, G., Torbenson, M.S., Daniel, H.D., Azad, N.S., Diaz, L.A. Jr., Donehower, R.C., Hirose, K., Ahuja, N., Pawlik, T.M., Choti, M.A., Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119:23 (2013), 4137–4144.
23. [23] Stremitzer, S., Stift, J., Gruenberger, B., Tamandl, D., Aschacher, T., Wolf, B., Wrba, F., Gruenberger, T., KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br. J. Surg. 99:11 (2012), 1575–1582.
24. [24] Isella, C., Mellano, A., Galimi, F., Petti, C., Capussotti, L., De Simone, M., Bertotti, A., Medico, E., Muratore, A., MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann. Surg. 257:6 (2013), 1089–1095.
25. [25] Kemeny, N.E., Chou, J.F., Capanu, M., Gewirtz, A.N., Cercek, A., Kingham, T.P., Jarnagin, W.R., Fong, Y.C., DeMatteo, R.P., Allen, P.J., Shia, J., Ang, C., Vakiani, E., D'Angelica, M.I., KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 120:24 (2014), 3965–3971.
26. [26] Margonis, G.A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M.A., Pawlik, T.M., Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann. Surg. Oncol. 22:13 (2015), 4158–4165.
27. [27] Schirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., Yang, D., Marmorino, F., Pasquini, G., Sensi, E., Lupi, C., De Maglio, G., Borrelli, N., Pizzolitto, S., Fasola, G., Bertorelle, R., Rugge, M., Fontanini, G., Zagonel, V., Loupakis, F., Falcone, A., BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br. J. cancer 112:12 (2015), 1921–1928.
28. [28] Margonis, G.A., Kim, Y., Spolverato, G., Ejaz, A., Gupta, R., Cosgrove, D., Anders, R., Karagkounis, G., Choti, M.A., Pawlik, T.M., Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 150:8 (2015), 722–729.
29. [29] Al-Mulla, F., Milner-White, E.J., Going, J.J., Birnie, G.D., Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J. Pathaol. 187:4 (1999), 433–438.
30. [30] Bollag, G., McCormick, F., Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays. Methods Enzym. 255 (1995), 161–170.
31. [31] Guerrero, S., Casanova, I., Farre, L., Mazo, A., Capella, G., Mangues, R., K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 60:23 (2000), 6750–6756.
32. [32] Seeburg, P.H., Colby, W.W., Capon, D.J., Goeddel, D.V., Levinson, A.D., Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:5989 (1984), 71–75.
33. [33] Kim, M.J., Lee, H.S., Kim, J.H., Kim, Y.J., Kwon, J.H., Lee, J.O., Bang, S.M., Park, K.U., Kim, D.W., Kang, S.B., Kim, J.S., Lee, J.S., Lee, K.W., Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer, 12, 2012, 347.
34. [34] Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R.N., Christie, M., Drummond, K.J., Thomson, B.N., Usatoff, V., Evans, P.M., Pick, A.W., Knight, S., Carne, P.W., Berry, R., Polglase, A., McMurrick, P., Zhao, Q., Busam, D., Strausberg, R.L., Domingo, E., Tomlinson, I.P., Midgley, R., Kerr, D., Sieber, O.M., KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin. cancer Res. 17:5 (2011), 1122–1130 an official journal of the American Association for Cancer Research.
35. [35] Pereira, A.A., Rego, J.F., Morris, V., Overman, M.J., Eng, C., Garrett, C.R., Boutin, A.T., Ferrarotto, R., Lee, M., Jiang, Z.Q., Hoff, P.M., Vauthey, J.N., Vilar, E., Maru, D., Kopetz, S., Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br. J. cancer 112:3 (2015), 424–428.
36. [36] Shindoh, J., Nishioka, Y., Yoshioka, R., Sugawara, T., Sakamoto, Y., Hasegawa, K., Hashimoto, M., Kokudo, N., KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann. Surg. Oncol., 2016.
37. [37] Urosevic, J., Garcia-Albeniz, X., Planet, E., Real, S., Cespedes, M.V., Guiu, M., Fernandez, E., Bellmunt, A., Gawrzak, S., Pavlovic, M., Mangues, R., Dolado, I., Barriga, F.M., Nadal, C., Kemeny, N., Batlle, E., Nebreda, A.R., Gomis, R.R., Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat. Cell Biol. 16:7 (2014), 685–694.
38. [38] Huang, C.J., Teng, H.W., Chien, C.C., Lin, J.K., Yang, S.H., Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PloS One, 8(6), 2014 e65117.
39. [39] Teng, H.W., Huang, Y.C., Lin, J.K., Chen, W.S., Lin, T.C., Jiang, J.K., Yen, C.C., Li, A.F., Wang, H.W., Chang, S.C., Lan, Y.T., Lin, C.C., Wang, H.S., Yang, S.H., BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J. Surg. Oncol. 106:2 (2012), 123–129.
40. [40] Umeda, Y., Nagasaka, T., Mori, Y., Sadamori, H., Sun, D.S., Shinoura, S., Yoshida, R., Satoh, D., Nobuoka, D., Utsumi, M., Yoshida, K., Yagi, T., Fujiwara, T., Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J. Hepato–biliary–pancreatic Sci. 20:2 (2013), 223–233.
41. [41] De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., Penault-Llorca, F., Rougier, P., Vincenzi, B., Santini, D., Tonini, G., Cappuzzo, F., Frattini, M., Molinari, F., Saletti, P., De Dosso, S., Martini, M., Bardelli, A., Siena, S., Sartore-Bianchi, A., Tabernero, J., Macarulla, T., Di Fiore, F., Gangloff, A.O., Ciardiello, F., Pfeiffer, P., Qvortrup, C., Hansen, T.P., Van Cutsem, E., Piessevaux, H., Lambrechts, D., Delorenzi, M., Tejpar, S., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet. Oncol. 11:8 (2010), 753–762.